Author

DE Furst

UCLA, Pacific Medical Clinic, Univ. of Washington, University of Florence, Italy - Cited by 1,00,836 - Rheumatology - Scleroderma - Rheumatoid Arthritis - Lupus - Vasculitis

Biography

Dr Daniel E. Furst is Professor of Medicine at the University of California (emeritus), Los Angeles (UCLA), Medical Center, David Geffen School of Medicine, Department of Medicine, Division of Rheumatology. He is also an Adjunct Professor at the University of Washington, Seattle Washington and a Research Professor at the University of Florence, Florence, Italy.
Title
Cited by
Year
Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge …
Y Wang, G Du, G Zhang, M Matucci-Cerinic, DE FurstAnnals of the Rheumatic Diseases 81 (10), e192-e192, 2022202
24
2022
Barriers and facilitators to physical activity for people with scleroderma: A scleroderma patient‐Centered Intervention Network Cohort Study
S Harb, S Peláez, ME Carrier, L Kwakkenbos, SJ Bartlett, M Hudson, ...Arthritis Care & Research 74 (8), 1300-1310, 2022202
11
2022
New and Updated Recommendations for the Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis and Idiopathic Chronic Anterior Uveitis
I Foeldvari, I Maccora, H Petrushkin, N Rahman, J Anton, J de Boer, ...Arthritis care & research 75 (5), 975-982, 2023202
10
2023
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy
A Shah, J Storek, R Woolson, A Pinckney, L Keyes-Elstein, PK Wallace, ...Rheumatology 61 (10), 4155-4162, 2022202
7
2022
Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort
M Elhai, N Sritharan, M Boubaya, A Balbir-Gurman, E Siegert, E Hachulla, ...The Lancet Rheumatology 4 (11), e78-e794, 2022202
5
2022
Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial
D Khanna, P Caldron, RW Martin, S Kafaja, R Spiera, S Shahouri, A Shah, ...Arthritis & Rheumatology 74 (8), 1399-1408, 2022202
5
2022
Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial
VK Ranganath, A La Cava, S Vangala, J Brook, TA Kermani, DE Furst, ...Rheumatology 62 (2), 6-74, 2023202
5
2023
Predictive model of risk and severity of enteritis in systemic lupus erythematosus
W Zhang, G Huang, J Lin, Q Lin, K Zheng, S Hu, S Zheng, G Du, ...Lupus 31 (10), 1226-1236, 2022202
4
2022
Clinical and molecular findings after autologous stem cell transplantation or cyclophosphamide for scleroderma: handling missing longitudinal data
L Keyes‐Elstein, A Pinckney, E Goldmuntz, B Welch, JM Franks, ...Arthritis Care & Research 75 (2), 07-16, 20220
3
2023
Systemic sclerosis-associated interstitial lung disease in the EUSTAR database: analysis by region
A Lescoat, D Huscher, N Schoof, P Airò, J de Vries-Bouwstra, ...Rheumatology 62 (6), 2178-2188, 20220
3
2023
Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease
M Hughes, Y Allanore, M Baron, F Del Galdo, CP Denton, T Frech, ...The Lancet Rheumatology 4 (11), e795-e80, 2022202
3
2022
Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model
A Garaiman, K Steigmiller, C Gebhard, C Mihai, R Dobrota, C Bruni, ...Rheumatology 62 (SI), SI91-SI100, 20220
3
2023
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis
Biological and clinical insights from a randomized phase study of an anti-oncostatin M monoclonal antibody in systemic sclerosisCP Denton, F Del Galdo, D Khanna, MC Vonk, L Chung, SR Johnson, ...Rheumatology 6 (1), 34-4, 030
2
2023
A 24‐Week, Phase IIa, Randomized, Double‐blind, Placebo‐controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)
A 4‐Week, Phase IIa, Randomized, Double‐blind, Placebo‐controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)D Khanna, CP Denton, DE Furst, MD Mayes, M Matucci‐Cerinic, V Smith, ...Arthritis & Rheumatology, 030
2
2023
Myeloablation Followed by Hematopoietic Stem Cell Transplantation Leads to Long-term Normalization of Systemic Sclerosis Molecular Signatures
N Wareing, X Wang, L Keyes-Elstein, E Goldmuntz, M Lyons, ...ARTHRITIS & RHEUMATOLOGY 74, 1041-1044, 0
2
2022
Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis
JZ Adamska, A Zia, MS Bloom, LJ Crofford, DE Furst, E Goldmuntz, ...Annals of the rheumatic diseases 8 (3), 357-364, 030
2
2023
The disconnect between visual assessment of air trapping and lung physiology for assessment of small airway disease in scleroderma-related interstitial lung disease: An …
SS Bae, L Pourzand, G Hyun Kim, BE Villegas, A Oh, DE Furst, J Goldin, ...Journal of Scleroderma and Related Disorders 7 (), 117-17, 0
2
2022
Sex influence on outcomes of patients with systemic sclerosis–associated interstitial lung disease: a EUSTAR database analysis
C Campochiaro, AM Hoffmann-Vold, J Avouac, J Henes, ...Rheumatology, keac660, 2022202
1
2022
Discrepancy between multibiomarker disease activity and clinical disease activity scores in patients with persistently active rheumatoid arthritis
R Fleischmann, J Liu, J Zhu, OG Segurado, DE FurstArthritis Care & Research 74 (9), 477-483, 2022202
1
2022
Application of logistic regression and machine learning methods for idiopathic inflammatory myopathies malignancy prediction
W Zhang, G Huang, K Zheng, J Lin, S Hu, S Zheng, G Du, G Zhang, ...Clinical and Experimental Rheumatology 4 (2), 330-339, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=c2A7RtcAAAAJ&hl=en

Cited by
Citations 100836
h-index 138
i10-index 663
Recommended Journals
Open Access Journals